Shares of Dr Reddy's Laboratories

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

today fell by nearly 5 per cent after the company received 13

observations from the US health regulator for its formulation

manufacturing facility at Duwada, Visakhapatnam.

The stock went down by 4.6 per cent to Rs 2,720 -- its

52-week low level -- on BSE.

On NSE, it slipped 4.64 per cent to hit its one-year low

of Rs 2,714.50.

The stock was the worst performer among the bluechips on

both the Sensex and Nifty

"The audit of company's formulation manufacturing facility

at Duwada, Visakhapatnam, by the USFDA, has been completed on

March 8, 2017. The company has been issued Form 483 with 13

observations, which the company is addressing," Dr Reddy's

Laboratories said in a BSE filing.

The firm, however, did not specify the observations.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)